Siegfried Holding AG
SFZN
Κατάταξη σε μετοχές
#4105
Siegfried Holding AG, together with its subsidiaries, engages in contract... Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Τιμή μετοχής
$88.34
Κεφαλαιοποίηση
$3.87B
Αλλαγή (1 ημέρα)
1.68%
Αλλαγή (1 έτος)
-12.97%
Χώρα
CH
Εμπόριο Siegfried Holding AG (SFZN)
Κατηγορία
Healthcare
Κέρδη για την Siegfried Holding AG (SFZN)
Κέρδη τον 2026 TTM: 0
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Siegfried Holding AG, τα τρέχοντα κέρδη της εταιρείας είναι 0. Το 2026, η εταιρεία παρουσίασε κέρδη 0, ίσο με των κερδών του 2026 που ήταν 0. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Siegfried Holding AG από 2002 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2025 | $262.95M | 21.02% |
| 2024 | $217.28M | 21.51% |
| 2023 | $178.81M | -24.44% |
| 2022 | $236.63M | 70.46% |
| 2021 | $138.82M | 68.39% |
| 2020 | $82.44M | 54.98% |
| 2019 | $53.19M | -25.42% |
| 2018 | $71.32M | 20.14% |
| 2017 | $59.37M | 73.97% |
| 2016 | $34.13M | -7.94% |
| 2015 | $37.07M | 15.84% |
| 2014 | $32.00M | -43.19% |
| 2013 | $56.32M | 239.87% |
| 2012 | $16.57M | 48.10% |
| 2011 | $11.19M | -312.32% |
| 2010 | $-5.27M | -86.49% |
| 2009 | $-39.02M | -52.71% |
| 2008 | $-82.51M | -453.96% |
| 2007 | $23.31M | 6.35% |
| 2006 | $21.92M | -32.38% |
| 2005 | $32.41M | 96.31% |
| 2004 | $16.51M | -65.51% |
| 2003 | $47.87M | -4.28% |
| 2002 | $50.01M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
